About Acer Therapeutics

Acer Therapeutics is developing therapies with established clinical proof-of-concept for the treatment of serious, ultra-rare diseases with critical unmet medical need. We are committed to delivering life-changing benefits to patients who lack treatment options.

Our late-stage clinical pipeline includes two candidates for severe genetic disorders for which there are currently no FDA-approved treatments: Edsivo™ (celiprolol) for vascular Ehlers-Danlos Syndrome (vEDS) and ACER-001 for Maple Syrup Urine Disease (MSUD). We are also advancing ACER-001 for the treatment of Urea Cycle Disorders (UCDs).